1978
DOI: 10.1002/ijc.2910210510
|View full text |Cite
|
Sign up to set email alerts
|

Proteolytic release of antigenic fragments corresponding to normal fecal antigen and non‐specific cross‐reacting antigen from carcinoembryonic antigen

Abstract: Three immunogenic parts have so far been identified in the carcinoembryonic antigen (CEA) molecule. These are: determinants cross-reactint with the normal fecal antigen (NFA) (NFA determinant); determinants cross-reacting antigen (NCA) (NCA determinant); and determinants which appear to be more cancer-specific (cancer determinant). The chemical nature of these parts of the CEA molecule was investigated by digestion with proteolytic enzymes together with anti-CEA preparations with which these three immunogenic … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
9
0

Year Published

1984
1984
2020
2020

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 44 publications
(10 citation statements)
references
References 21 publications
(8 reference statements)
1
9
0
Order By: Relevance
“…These NCAs have been de tected using a variety of methods [17][18][19][20][21][22]. This family of CEA-related molecules is complex and has made the true tissue speci ficity of CEA difficult to interpret.…”
Section: Introductionmentioning
confidence: 99%
“…These NCAs have been de tected using a variety of methods [17][18][19][20][21][22]. This family of CEA-related molecules is complex and has made the true tissue speci ficity of CEA difficult to interpret.…”
Section: Introductionmentioning
confidence: 99%
“…Mlcroscale immunodlffusion tests were carried out in a 1.2% agarose layer as described previously (47).…”
Section: Western Blotting Analysesmentioning
confidence: 99%
“…These include blood assays to monitor tumor burden (13,14), immunohistochemical analyses of tissue samples to detect tumor cells (15,16), tumor imaging with radiolabeled MAbs (17,18), and MAb-guided therapy (19,20). Since more than 20 structurally related antigens, such as nonspecific cross-reacting antigen (NCA) (21,22), normal fecal antigen (NFA) (23,24,25,26), or biliary glycoprotein (BGP) (27), have been found in various human tissues or body fluids as products of the CEA gene family members (5), elucidation of the specificity of anti-CEA MAbs is very important. Their specificity has been evaluated by several approaches including the analysis of cross-reactivity with the CEA-related antigens (28,29,30), immuno-histochemical reactivity with a variety of normal or malignant tissues (31,32,33), and competitive binding activity among MAbs (29,30,34).…”
Section: Introductionmentioning
confidence: 99%